サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1478664

糖尿病性ニューロパチー治療市場、シェア、規模、動向、産業分析レポート：疾患タイプ別、薬剤クラス別、流通チャネル別、地域別、セグメント別予測、2024年～2032年

Diabetic Neuropathy Treatment Market Share, Size, Trends, Industry Analysis Report, By Disorder Type; By Drug Class; By Distribution Channel; By Region; Segment Forecast, 2024- 2032

出版日
ページ情報
英文 115 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
糖尿病性ニューロパチー治療市場、シェア、規模、動向、産業分析レポート：疾患タイプ別、薬剤クラス別、流通チャネル別、地域別、セグメント別予測、2024年～2032年
出版日: 2024年04月24日
発行: Polaris Market Research
ページ情報: 英文 115 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界の糖尿病性ニューロパチー治療市場規模は2032年までに95億7,000万米ドルに達する見込みです。このレポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

糖尿病性ニューロパチーは、糖尿病によって引き起こされる神経障害に起因するもので、しびれ、痛み、脱力感などの症状が特徴で、この症状を持つ人の最大半数が罹患しています。糖尿病性ニューロパチー市場の成長にはいくつかの要因が寄与しています。座りがちなライフスタイル、不健康な食習慣、若年層におけるストレスによる肥満などが、糖尿病性ニューロパチーの発症リスクを高めています。さらに、喫煙率の増加や世界の糖尿病有病率の上昇といった要因が、ニューロパチー治療の見込み患者層を拡大し、市場力学を変化させています。

糖尿病有病率の上昇は、人口の高齢化や糖尿病合併症に対する意識の高まりと相まって、ニューロパチー治療薬の需要を牽引しています。治療法の選択肢や治療法の発展は、市場の拡大をさらに後押しします。さらに、糖尿病とその合併症に罹患しやすい老年人口の増加が、ニューロパチー治療の必要性を高めています。

糖尿病に対する認識を高め、研究開発努力を支援する政府の取り組みも市場拡大に寄与しています。末梢神経障害を伴う様々な疾患を包含する末梢神経障害は、世界の老年人口と肥満人口の増加によって悪化しています。糖尿病との関連を考えると、糖尿病有病率の上昇が予測期間中の市場成長を促進すると予想されます。

糖尿病が増加し続けるにつれて、糖尿病の一般的な合併症である糖尿病性ニューロパチーの発生率も増加しています。このような有病率の増加は、神経障害症状を管理し、患者の生活の質を向上させるための効果的な治療に対する需要の高まりと直結しています。さらに、医療技術や製薬研究の進歩は、糖尿病性ニューロパチーに特化した革新的な治療法や薬剤の開発に貢献しており、市場の成長をさらに促進しています。さらに、肥満や座りがちな生活習慣などのライフスタイル要因と相まって、高齢化人口の増加が市場の拡大に寄与しています。

糖尿病性ニューロパチー治療市場レポートハイライト

2023年、糖尿病性ニューロパチー治療薬市場では、非ステロイド性抗炎症薬（NSAIDs）分野が最大の市場シェアを占めました。NSAIDsは一般に、処方薬や医療処置などの他の治療オプションに比べて手ごろな価格です。

病院セグメントは予測期間中、最も速いCAGRで成長すると予想されています。病院薬局では、小売薬局や他のヘルスケア環境よりも幅広い糖尿病性ニューロパチー治療薬を入手できる可能性があります。

2023年には、北米が大きな市場シェアの伸びを占めました。同地域の医療費の高さは、強固な保険適用や償還政策と相まって、患者が幅広い糖尿病性ニューロパチー治療薬にアクセスできることを保証しています。

アジア太平洋地域は、糖尿病性ニューロパチー治療市場において予測期間中にCAGRの大幅な成長が見込まれています。アジア太平洋地域では、ヘルスケア専門家や一般住民の間で、糖尿病および糖尿病性ニューロパチーを含むその合併症に対する認識が高まっています。認知度の向上は、早期診断、積極的な管理、糖尿病性ニューロパチー治療薬の需要増加につながります。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の糖尿病性ニューロパチー治療市場の洞察

  • 薬物クラスのスナップショット
  • 糖尿病性ニューロパチー治療市場力学
    • 促進要因と機会
      • 世界中で糖尿病の罹患率が増加しており、市場の成長が加速すると予測されています。
      • 主要企業による研究開発活動の拡大が世界の糖尿病性ニューロパチー市場を活性化
    • 抑制要因と課題
      • 高額な医薬品が市場の成長を妨げると予想される
  • PESTEL分析
  • 糖尿病性ニューロパチー治療市場の薬剤クラスの動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 世界の糖尿病性ニューロパチー治療市場：疾患タイプ別

  • 主な調査結果
  • イントロダクション
  • 末梢神経ニニューロパチー
  • 自律神経ニューロパチー
  • 近位神経ニニューロパチー
  • 局所性ニニューロパチー

第6章 世界の糖尿病性ニューロパチー治療市場：流通チャネル別

  • 主な調査結果
  • イントロダクション
  • 局所神経障害
  • クリニック
  • 小売薬局
  • その他

第7章 世界の糖尿病性ニューロパチー治療市場：薬剤クラス別

  • 主な調査結果
  • イントロダクション
  • カプサイシン
  • オピオイド
  • 非ステロイド性抗炎症薬（NSAID）
  • 抗うつ薬
  • その他

第8章 世界の糖尿病性ニューロパチー治療市場：地域別

  • 主な調査結果
  • イントロダクション
    • 糖尿病性ニューロパチー治療市場評価：地域、2019-2032年
  • 北米
    • 北米：疾患タイプ別、2019年～2032年
    • 北米：薬剤クラス別、2019-2032年
    • 北米：流通チャネル別、2019年～2032年
    • 米国
    • カナダ
  • 欧州
    • 欧州：疾患タイプ別、2019-2032年
    • 欧州：薬剤クラス別、2019-2032年
    • 欧州：流通チャネル別、2019年～2032年
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
  • アジア太平洋地域
    • アジア太平洋地域：疾患タイプ別、2019-2032年
    • アジア太平洋地域：薬剤クラス別、2019-2032年
    • アジア太平洋地域：流通チャネル別、2019年～2032年
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
  • 中東・アフリカ
    • 中東およびアフリカ：疾患タイプ別、2019-2032年
    • 中東およびアフリカ：薬剤クラス別、2019-2032年
    • 中東・アフリカ：流通チャネル別、2019年～2032年
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
  • ラテンアメリカ
    • ラテンアメリカ：疾患タイプ別、2019-2032年
    • ラテンアメリカ：薬剤クラス別、2019-2032年
    • ラテンアメリカ：流通チャネル別、2019年～2032年
    • メキシコ
    • ブラジル
    • アルゼンチン

第9章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第10章 企業プロファイル

  • Abbott
  • Astellas Pharma Inc
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals Ltd
  • Janssen Pharmaceuticals, Inc
  • Lupin Pharmaceuticals
  • Medtronic PLC
  • Novartis
  • Pfizer. Inc
図表

List of Tables

  • Table 1 Global Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 2 Global Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 3 Global Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 4 Diabetic Neuropathy Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 6 North America: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 7 North America: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 8 U.S.: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 9 U.S.: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 10 U.S.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 11 Canada: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 12 Canada: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 13 Canada: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 14 Europe: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 15 Europe: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 16 Europe: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 17 UK: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 18 UK: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 19 UK: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 20 France: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 21 France: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 22 France: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 23 Germany: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 25 Germany: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 26 Italy: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 27 Italy: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 28 Italy: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 29 Spain: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 30 Spain: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 31 Spain: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 35 Russia: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 36 Russia: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 37 Russia: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 41 China: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 42 China: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 43 China: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 44 India: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 45 India: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 46 India: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 50 Japan: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 51 Japan: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 52 Japan: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 56 South Korea: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 57 South Korea: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 58 South Korea: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 65 UAE: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 66 UAE: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 67 UAE: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 68 Israel: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 69 Israel: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 70 Israel: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 71 South Africa: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 72 South Africa: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 73 South Africa: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 74 Latin America: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 75 Latin America: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 76 Latin America: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 77 Mexico: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 78 Mexico: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 79 Mexico: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 80 Brazil: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 81 Brazil: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 82 Brazil: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 83 Argentina: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • Table 84 Argentina: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 85 Argentina: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Diabetic Neuropathy Treatment Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Distribution Channel
  • Figure 7. Global Diabetic Neuropathy Treatment Market, by Distribution Channel, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Disorder Type
  • Figure 9. Global Diabetic Neuropathy Treatment Market, by Disorder Type, 2022 & 2032 (USD Billion)
  • Figure 10. Market by Drug Class
  • Figure 11. Global Diabetic Neuropathy Treatment Market, by Drug Class, 2022 & 2032 (USD Billion)
  • Figure 12. Diabetic Neuropathy Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Diabetic Neuropathy Treatment Market
目次
Product Code: PM4868

The global diabetic neuropathy treatment market size is expected to reach USD 9.57 billion by 2032, according to a new study by Polaris Market Research. The report "Diabetic Neuropathy Treatment Market Share, Size, Trends, Industry Analysis Report, By Disorder Type (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy); By Drug Class; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Diabetic neuropathy, resulting from nerve damage triggered by diabetes, is characterized by symptoms like numbness, pain, and weakness, affecting up to half of those with the condition. Several factors contribute to the growth of the diabetic neuropathy market. The sedentary lifestyle, unhealthy eating habits, and stress-induced obesity in younger individuals heighten the risk of developing diabetic neuropathy. Furthermore, factors like increased smoking rates and the global prevalence of diabetes expand the prospective patient pool for neuropathy treatments, altering market dynamics.

The rising prevalence of diabetes, combined with an aging population and increased awareness of diabetic complications, drives the demand for neuropathy treatments. Advancements in treatment options and therapeutic developments further propel market expansion. Additionally, the growing geriatric population, prone to diabetes and its complications, amplifies the need for neuropathy treatments.

Government initiatives to raise diabetes awareness and support research and development efforts also contribute to market growth. Peripheral neuropathy, which encompasses various conditions involving peripheral nerve damage, is exacerbated by the global rise in geriatric and obese populations. Given its association with diabetes, the escalating prevalence of diabetes is expected to drive market growth in the forecast period.

As diabetes continues to rise, so does the incidence of diabetic neuropathy, a common complication of the disease. This increasing prevalence directly correlates with a higher demand for effective treatments to manage neuropathic symptoms and improve patient's quality of life. Additionally, advancements in medical technology and pharmaceutical research contribute to the development of innovative therapies and medications tailored specifically for diabetic neuropathy, further driving market growth. Moreover, the growing aging population, coupled with lifestyle factors such as obesity and sedentary habits, contributes to the expanding market.

Diabetic Neuropathy Treatment Market Report Highlights

In 2023, the non-steroidal anti-inflammatory drugs (NSAIDs) segment accounted for the largest market share in the diabetic neuropathy treatment market. NSAIDs are generally more affordable compared to other treatment options, such as prescription medications or medical procedures.

The hospital segment is expected to grow at the fastest CAGR during the forecast period. Hospital pharmacies may have access to a broader range of diabetic neuropathy medications than retail pharmacies or other healthcare settings.

In 2023, North America accounted for the growth of a significant market share. The region's high healthcare expenditures, coupled with robust insurance coverage and reimbursement policies, ensure that patients have access to a wide range of diabetic neuropathy treatments.

The Asia Pacific region is expected for significant growth in CAGR during the forecast period in the diabetic neuropathy treatment market. There is a growing awareness of diabetes and its complications, including diabetic neuropathy, among healthcare professionals and the general population in the Asia Pacific region. Increased awareness leads to earlier diagnosis, proactive management, and a higher demand for diabetic neuropathy treatments.

The global key market players are Abbott, Astellas Pharma Inc., Boehringer Ingelheim GmbH, Eli Lilly and Company, Glenmark Pharmaceuticals Ltd, Janssen Pharmaceuticals, Inc., Lupin Pharmaceuticals, Medtronic PLC, Novartis, Pfizer. Inc.

Polaris Market Research has segmented the diabetic neuropathy treatment market report based on disorder type, drug class, distribution channel, and region.

Diabetic Neuropathy Treatment, Disorder Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Peripheral Neuropathy
  • Autonomic Neuropathy
  • Proximal Neuropathy
  • Focal Neuropathy

Diabetic Neuropathy Treatment, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

  • Capsaicin
  • Opioid
  • Morphine
  • Others
  • Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
  • Ibuprofen
  • Naproxen
  • Others
  • Antidepressants
  • Tricyclic Antidepressants (TCAs)
  • Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Anticonvulsant Drugs
  • Other

Diabetic Neuropathy Treatment, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospitals
  • Clinics
  • Retail Pharmacies
  • Other

Diabetic Neuropathy Treatment, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Diabetic Neuropathy Treatment Market Insights

  • 4.1. Diabetic Neuropathy Treatment Market - Drug Class Snapshot
  • 4.2. Diabetic Neuropathy Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing prevalence of diabetes worldwide have been projected to spur market
      • 4.2.1.2. Growing research and development activities by key players to fuel the global diabetic neuropathy market
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High-cost medication is expected to hinder the growth of the market
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Diabetic Neuropathy Treatment Market Drug Class Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Diabetic Neuropathy Treatment Market, by Disorder Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
  • 5.3. Peripheral Neuropathy
    • 5.3.1. Global Diabetic Neuropathy Treatment Market, by Peripheral Neuropathy, by Region, 2019-2032 (USD Billion)
  • 5.4. Autonomic Neuropathy
    • 5.4.1. Global Diabetic Neuropathy Treatment Market, by Autonomic Neuropathy, by Region, 2019-2032 (USD Billion)
  • 5.5. Proximal Neuropathy
    • 5.5.1. Global Diabetic Neuropathy Treatment Market, by Proximal Neuropathy, by Region, 2019-2032 (USD Billion)
  • 5.6. Focal Neuropathy
    • 5.6.1. Global Diabetic Neuropathy Treatment Market, by Focal Neuropathy, by Region, 2019-2032 (USD Billion)

6. Global Diabetic Neuropathy Treatment Market, by Distribution Channel

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 6.3. Focal Neuropathy
    • 6.3.1. Global Diabetic Neuropathy Treatment Market, by Focal Neuropathy, by Region, 2019-2032 (USD Billion)
  • 6.4. Clinics
    • 6.4.1. Global Diabetic Neuropathy Treatment Market, by Clinics, by Region, 2019-2032 (USD Billion)
  • 6.5. Retail Pharmacies
    • 6.5.1. Global Diabetic Neuropathy Treatment Market, by Retail Pharmacies, by Region, 2019-2032 (USD Billion)
  • 6.6. Other
    • 6.6.1. Global Diabetic Neuropathy Treatment Market, by Other, by Region, 2019-2032 (USD Billion)

7. Global Diabetic Neuropathy Treatment Market, by Drug Class

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
  • 7.3. Capsaicin
    • 7.3.1. Global Diabetic Neuropathy Treatment Market, by Capsaicin, By Region, 2019-2032 (USD Billion)
  • 7.4. Opioid
    • 7.4.1. Global Diabetic Neuropathy Treatment Market, by Opioid, By Region, 2019-2032 (USD Billion)
    • 7.4.2. Morphine
      • 7.4.2.1. Global Diabetic Neuropathy Treatment Market, by Morphine, By Region, 2019-2032 (USD Billion)
    • 7.4.3. Others
      • 7.4.3.1. Global Diabetic Neuropathy Treatment Market, by Others, By Region, 2019-2032 (USD Billion)
  • 7.5. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
    • 7.5.1. Global Diabetic Neuropathy Treatment Market, by Non-Steroidal Anti-inflammatory Drugs (NSAIDs), By Region, 2019-2032 (USD Billion)
    • 7.5.2. Ibuprofen
      • 7.5.2.1. Global Diabetic Neuropathy Treatment Market, by Ibuprofen, By Region, 2019-2032 (USD Billion)
    • 7.5.3. Naproxen
      • 7.5.3.1. Global Diabetic Neuropathy Treatment Market, by Naproxen, By Region, 2019-2032 (USD Billion)
    • 7.5.4. Others
      • 7.5.4.1. Global Diabetic Neuropathy Treatment Market, by Others, By Region, 2019-2032 (USD Billion)
  • 7.6. Antidepressants
    • 7.6.1. Global Diabetic Neuropathy Treatment Market, by Antidepressants, By Region, 2019-2032 (USD Billion)
    • 7.6.2. Tricyclic Antidepressants (TCAs)
      • 7.6.2.1. Global Diabetic Neuropathy Treatment Market, by Tricyclic Antidepressants (TCAs), By Region, 2019-2032 (USD Billion)
    • 7.6.3. Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
      • 7.6.3.1. Global Diabetic Neuropathy Treatment Market, by Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), By Region, 2019-2032 (USD Billion)
    • 7.6.4. Selective Serotonin Reuptake Inhibitors (SSRIs)
      • 7.6.4.1. Global Diabetic Neuropathy Treatment Market, by Selective Serotonin Reuptake Inhibitors (SSRIs), By Region, 2019-2032 (USD Billion)
    • 7.6.5. Anticonvulsant Drugs
      • 7.6.5.1. Global Diabetic Neuropathy Treatment Market, by Anticonvulsant Drugs, By Region, 2019-2032 (USD Billion)
  • 7.7. Other
    • 7.7.1. Global Diabetic Neuropathy Treatment Market, by Other, By Region, 2019-2032 (USD Billion)

8. Global Diabetic Neuropathy Treatment Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Diabetic Neuropathy Treatment Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Diabetic Neuropathy Treatment Market - North America
    • 8.3.1. North America: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.3.3. North America: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.3.4. Diabetic Neuropathy Treatment Market - U.S.
      • 8.3.4.1. U.S.: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.3.5. Diabetic Neuropathy Treatment Market - Canada
      • 8.3.5.1. Canada: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.4. Diabetic Neuropathy Treatment Market - Europe
    • 8.4.1. Europe: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.4.4. Diabetic Neuropathy Treatment Market - UK
      • 8.4.4.1. UK: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.4.5. Diabetic Neuropathy Treatment Market - France
      • 8.4.5.1. France: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.4.6. Diabetic Neuropathy Treatment Market - Germany
      • 8.4.6.1. Germany: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.4.7. Diabetic Neuropathy Treatment Market - Italy
      • 8.4.7.1. Italy: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.4.8. Diabetic Neuropathy Treatment Market - Spain
      • 8.4.8.1. Spain: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.4.9. Diabetic Neuropathy Treatment Market - Netherlands
      • 8.4.9.1. Netherlands: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.4.10. Diabetic Neuropathy Treatment Market - Russia
      • 8.4.10.1. Russia: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.5. Diabetic Neuropathy Treatment Market - Asia Pacific
    • 8.5.1. Asia Pacific: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.5.4. Diabetic Neuropathy Treatment Market - China
      • 8.5.4.1. China: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.5.5. Diabetic Neuropathy Treatment Market - India
      • 8.5.5.1. India: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.5.6. Diabetic Neuropathy Treatment Market - Malaysia
      • 8.5.6.1. Malaysia: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.5.7. Diabetic Neuropathy Treatment Market - Japan
      • 8.5.7.1. Japan: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.5.8. Diabetic Neuropathy Treatment Market - Indonesia
      • 8.5.8.1. Indonesia: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.5.9. Diabetic Neuropathy Treatment Market - South Korea
      • 8.5.9.1. South Korea: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.6. Diabetic Neuropathy Treatment Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.6.4. Diabetic Neuropathy Treatment Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.6.5. Diabetic Neuropathy Treatment Market - UAE
      • 8.6.5.1. UAE: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.6.6. Diabetic Neuropathy Treatment Market - Israel
      • 8.6.6.1. Israel: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.6.7. Diabetic Neuropathy Treatment Market - South Africa
      • 8.6.7.1. South Africa: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.7. Diabetic Neuropathy Treatment Market - Latin America
    • 8.7.1. Latin America: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.7.4. Diabetic Neuropathy Treatment Market - Mexico
      • 8.7.4.1. Mexico: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.7.5. Diabetic Neuropathy Treatment Market - Brazil
      • 8.7.5.1. Brazil: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.7.6. Diabetic Neuropathy Treatment Market - Argentina
      • 8.7.6.1. Argentina: Diabetic Neuropathy Treatment Market, by Disorder Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Diabetic Neuropathy Treatment Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Diabetic Neuropathy Treatment Market, by Distribution Channel, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Abbott
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Astellas Pharma Inc
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Boehringer Ingelheim GmbH
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Eli Lilly and Company
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Glenmark Pharmaceuticals Ltd
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Janssen Pharmaceuticals, Inc
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Lupin Pharmaceuticals
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Medtronic PLC
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Novartis
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Pfizer. Inc
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development